This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis of brain tumours

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • around 3 in 20 (14%) people diagnosed with brain cancer in England and Wales survive their disease for ten years or more (2010-11)

  • around a fifth (19%) of people diagnosed with brain cancer in England and Wales survive their disease for five years or more (2010-11)

  • 4 in 10 (40%) people diagnosed with brain cancer in England and Wales survive their disease for one year or more (2010-11)

  • brain cancer survival is higher in men than women at one-year but similar at five- and ten-years

  • brain cancer survival in England is highest for people diagnosed aged under 40 years old (2009-2013)

  • around 6 in 10 people in England diagnosed with brain cancer aged 15-39 survive their disease for five years or more, compared with only 1 in 100 people diagnosed aged 80 and over (2009-2013)

  • brain cancer survival is improving and has doubled in the last 40 years in the UK.

Five-year survival for brain cancer is highest in the youngest men and women and decreases with increasing age. Five-year net survival in men ranges from 57% in 15-39 year-olds to 1% in 80-99 year-olds for patients diagnosed with brain cancer in England during 2009-2013. In women, five-year survival ranges from 62% to 1% in the same age groups.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.